Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer. 2021

Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China.

The results of numerous large randomized clinical trials (RCTs) have changed clinical practice in gastric cancer (GC). However, research waste (ie, unpublished data, inadequate reporting, or avoidable design limitations) is still a major challenge for evidence-based medicine. To determine the characteristics of GC RCTs in the past 20 years and the presence of research waste and to explore potential targets for improvement. In this cross-sectional study of GC RCTs, ClinicalTrials.gov was searched for phase 3 or 4 RCTs registered from January 2000 to December 2019 using the keyword gastric cancer. Independent investigators undertook assessments and resolved discrepancies via consensus. Data were analyzed from August through December 2020. The primary outcomes were descriptions of the characteristics of GC RCTs and the proportion of studies with signs of research waste. Research waste was defined as unpublished data, inadequate reporting, or avoidable design limitations. Publication status was determined by searching PubMed and Scopus databases. The adequacy of reporting was evaluated using the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline checklist. Avoidable design limitations were determined based on existing bias or lack of cited systematic literature reviews. In the analyses of research waste, 125 RCTs that ended after June 2016 without publication were excluded. A total of 262 GC RCTs were included. The number of RCTs increased from 25 trials in 2000 to 2004 to 97 trials in 2015 to 2019, with a greater increase among RCTs of targeted therapy or immunotherapy, which increased from 0 trials in 2000 to 2004 to 36 trials in 2015 to 2019. The proportion of RCTs that were multicenter was higher in non-Asian regions than in Asian regions (50 of 71 RCTs [70.4%] vs 96 of 191 RCTs [50.3%]; P = .004). The analysis of research waste included 137 RCTs, of which 81 (59.1%) were published. Among published RCTs, 65 (80.2%) were judged to be adequately reported and 63 (77.8%) had avoidable design defects. Additionally, 119 RCTs (86.9%) had 1 or more features of research waste. Study settings that included blinding (odds ratio [OR], 0.56; 95% CI, 0.33-0.93; P = .03), a greater number of participants (ie, ≥200 participants; OR, 0.07; 95% CI, 0.01-0.51; P = .01), and external funding support (OR, 0.22; 95% CI, 0.08-0.60; P = .004) were associated with lower odds of research waste. Additionally, 35 RCTs (49.3%) were referenced in guidelines, and 18 RCTs (22.2%) had their prospective data reused. To our knowledge, this study is the first to describe the characteristics of GC RCTs in the past 20 years, and it found a research waste burden, which may provide evidence for the development of rational RCTs and reduction of waste in the future.

UI MeSH Term Description Entries
D011642 Publications Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181) Publication
D012107 Research Design A plan for collecting and utilizing data so that desired information can be obtained with sufficient precision or so that an hypothesis can be tested properly. Experimental Design,Data Adjustment,Data Reporting,Design, Experimental,Designs, Experimental,Error Sources,Experimental Designs,Matched Groups,Methodology, Research,Problem Formulation,Research Methodology,Research Proposal,Research Strategy,Research Technics,Research Techniques,Scoring Methods,Adjustment, Data,Adjustments, Data,Data Adjustments,Design, Research,Designs, Research,Error Source,Formulation, Problem,Formulations, Problem,Group, Matched,Groups, Matched,Matched Group,Method, Scoring,Methods, Scoring,Problem Formulations,Proposal, Research,Proposals, Research,Reporting, Data,Research Designs,Research Proposals,Research Strategies,Research Technic,Research Technique,Scoring Method,Source, Error,Sources, Error,Strategies, Research,Strategy, Research,Technic, Research,Technics, Research,Technique, Research,Techniques, Research
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D014866 Waste Products Debris resulting from a process that is of no further use to the system producing it. The concept includes materials discharged from or stored in a system in inert form as a by-product of vital activities. (From Webster's New Collegiate Dictionary, 1981) Product, Waste,Products, Waste,Waste Product
D015706 Bibliometrics The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983) Bibliography, Statistical,Analysis, Bibliometric,Bibliographies, Statistical,Bibliometric Analysis,Statistical Bibliographies,Statistical Bibliography,Analyses, Bibliometric,Bibliometric Analyses
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D017326 Clinical Trials, Phase III as Topic Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries. Clinical Trials, Phase 3 as Topic,Drug Evaluation, FDA Phase 3 as Topic,Drug Evaluation, FDA Phase III as Topic,Evaluation Studies, FDA Phase 3 as Topic,Evaluation Studies, FDA Phase III as Topic
D017327 Clinical Trials, Phase IV as Topic Works about planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries. Clinical Trials, Phase 4 as Topic,Drug Evaluation, FDA Phase 4 as Topic,Drug Evaluation, FDA Phase IV as Topic,Evaluation Studies, FDA Phase 4 as Topic,Evaluation Studies, FDA Phase IV as Topic

Related Publications

Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
May 2024, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
January 2002, Surgical oncology clinics of North America,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
January 2010, Surgical oncology clinics of North America,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
October 2020, Journal of general internal medicine,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
October 2019, The British journal of surgery,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
October 2017, Surgical oncology clinics of North America,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
January 1989, Cancer surveys,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
May 1982, Cancer treatment reports,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
February 2010, Journal of investigative medicine : the official publication of the American Federation for Clinical Research,
Jun Lu, and Bin-Bin Xu, and Li-Li Shen, and Dong Wu, and Zhen Xue, and Hua-Long Zheng, and Jian-Wei Xie, and Jia-Bin Wang, and Jian-Xian Lin, and Qi-Yue Chen, and Long-Long Cao, and Mi Lin, and Ru-Hong Tu, and Ze-Ning Huang, and Ju-Li Lin, and Chang-Ming Huang, and Chao-Hui Zheng, and Ping Li
November 1995, Surgical endoscopy,
Copied contents to your clipboard!